New to Optrafair - The Leader in Office-Based Visual Electrophysiology
For the first time, Diopsys, Inc. will be joining thousands of practitioners at Optrafair, the UK's top optical exhibition. As the leader in office-based visual electrophysiology, the company is excited to introduce the clinical benefits of performing ERG and VEP vision tests right in the eye care practice.
Diopsys provides eye care specialists with objective, functional information of the vision system to aid in the early detection of vision disorders and enhance patient management through ERG and VEP vision testing. Results from these tests are not just for rare disorders, but also for the early diagnosis and management of more common diseases like glaucoma, AMD, and diabetic retinopathy.1-3
For instance, a study out of Bascom Palmer Eye Institute on glaucoma suspects showed that changes in pattern ERG results can be detected approximately 8 years sooner than changes in RNFL thickness as measured by OCT. The authors conclude, “This represents a substantial window for intervention before permanent loss of structure from glaucoma.”1
Diopsys has done more than any other company to advance the use of ERG and VEP in the clinical practice. Visual electrophysiology instruments have historically been expensive and cumbersome, and the tests difficult to perform and interpret. In response to these challenges, Diopsys created an accessible, in-office visual electrophysiology suite, including PERG, VEP, and ffERG vision tests.
To overcome the device and result interpretation issues, “We developed two different practice-friendly testing platforms, the Diopsys® NOVA™ cart system, and the Diopsys® ARGOS™ tabletop system. And through our extensive clinical research, we can now provide eye care specialists with clear test results that are color-coded based on documented reference ranges”, explains Joseph Fontanetta, Diopsys CEO.
The company’s participation in Optrafair represents a significant step forward in educating UK eye care professionals on both the accessibility and clinical utility of office-based visual electrophysiology testing.
Visit Diopsys at Booth H30
For more information:
1 Banitt et al. Progressive Loss of Retinal Ganglion Cell Function Precedes Structural Loss by Several Years in Glaucoma Suspects. IOVS, March 2013, Vol. 54, No. 3
2 Oner et al. Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Doc Ophthalmol. 2009 Aug;119(1):37-42.
3 Pescosolido et al. Role of Electrophysiology in the Early Diagnosis and Follow-Up of Diabetic Retinopathy. J Diabetes Res 2015 5;2015:319692.